Alector, Inc. (ALEC) Stock Price & Analysis
Alector, Inc. (ALEC) fell 1.99% to USD 2.46 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.
ALEC last closed at USD 2.51; the session ranged USD 2.44–2.58 on volume of 496,601 shares. Market capitalization is $274.68M, with a 52-week range of USD 1.09–3.4 (NMS). Source: Nexqual, September 8, 2026 at 05:44 UTC.
Key Statistics (as of September 8, 2026 at 05:44 UTC)
| Price | USD 2.46 |
|---|---|
| Change | ▼ 1.99% (down) |
| Previous Close | USD 2.51 |
| Open | USD 2.52 |
| Day Range | USD 2.44 – 2.58 |
| 52-Week Range | USD 1.09 – 3.4 |
| Volume | 496,601 shares |
| Market Cap | $274.68M |
| Exchange | NMS |
Technical Analysis (ALEC)
Nexqual's technical model rates ALEC "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.05 (neutral) |
| vs SMA50 | Above (USD 1.9) |
| MACD | 0.19 (positive) |
Analyst Ratings (ALEC)
Wall Street analysts rate ALEC "None" based on 5 analysts, with a mean price target of USD 3.1 (range USD 1–6), per Nexqual as of September 8, 2026 at 05:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 3.1 |
| High Target | USD 6 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 3 / 3 / 2 |
Earnings (ALEC)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $2.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.21 vs est -0.23 ▲ beat |
| 2026-03-31 | USD -0.21 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.34 vs est -0.36 ▲ beat |
| 2025-09-30 | USD -0.34 vs est -0.41 ▲ beat |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financials & Fundamentals (ALEC)
| Total Revenue | $13.86M |
|---|---|
| Revenue Growth (YoY) | -57.80% |
| Gross Margin | +0.00% |
| Operating Margin | -734.73% |
| Profit Margin | +0.00% |
| ROE | -385.11% |
| Current Ratio | 5.26 |
| Total Cash | $172.80M |
| Total Debt | $32.76M |
| Free Cash Flow | $-107.25M |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Financial Health Score (ALEC)
Nexqual rates Alector, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 05:44 UTC.
| Growth | Critical — Revenue -79% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $173M cash vs $33M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$107M, burning cash |
| Efficiency | Critical — ROE -385%, ROA -27.6% |
Ownership (ALEC)
| Insider Ownership | +9.61% |
|---|---|
| Institutional Ownership | +84.91% |
| Shares Outstanding | 111.66M |
| Float | 94.31M |
| Short % of Float | +5.60% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
Leadership (ALEC)
Alector, Inc. is led by Arnon Rosenthal (age 69), Co-Founder, CEO & Director, per Nexqual as of September 8, 2026 at 05:44 UTC.
| Co-Founder, CEO & Director | Arnon Rosenthal (age 69) |
|---|---|
| CFO & Chief Business Officer | Neil Berkley M.B.A., M.S. (age 51) |
| Senior Director of Corporate Communication & Investor Relations | Katie Hogan |
| Director of Antibody Discovery & Protein Engineering | Eric Brown |
Major Backers & Investors (ALEC)
Notable institutional backers of Alector, Inc. include TCG Crossover Management, LLC, Acadian Asset Management. LLC, Nantahala Capital Management, LLC, according to Nexqual as of September 8, 2026 at 05:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 8.96% |
| Acadian Asset Management. LLC | 3.95% |
| Nantahala Capital Management, LLC | 3.87% |
| Kynam Capital Management, LP | 3.41% |
| Merck & Co., Inc. | 3.18% |
| Balyasny Asset Management LP | 2.91% |
| 683 Capital Management LLC | 2.87% |
| Shaw D.E. & Co., Inc. | 2.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.62% |
| Vanguard Group | 8.7% |
Source: Nexqual, September 8, 2026 at 05:44 UTC.
From Alector, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
- Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
- The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.
- It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | USD 0.18 | ▲ 1.33% |
| STOK | Stoke Therapeutics, Inc. | USD 29.81 | ▼ 2.26% |
| DNLI | Denali Therapeutics Inc. | USD 22.28 | ▼ 2.49% |
| BDTX | Black Diamond Therapeutics, Inc | USD 2.12 | ▼ 0.93% |
| DTIL | Precision BioSciences, Inc. | USD 7.47 | ▲ 0.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.